MIRA INFORM REPORT
|
Report Date : |
17.01.2008 |
IDENTIFICATION
DETAILS
|
Name : |
FRIENDS PHARMA PRIVATE LIMITED |
|
|
|
|
Registered Office : |
2-Rasool Park, Ferozepur Road, Lahore |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
1993 |
|
|
|
|
Com. Reg. No.: |
0029342 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of
Pharmaceutical Products |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Business Name
FRIENDS PHARMA
(PRIVATE) LIMITED
Full Address
Registered Address
2-Rasool Park,
Ferozepur Road, Lahore, Pakistan
Tel 92
(42) 5935121, 5935122
Fax 92
(42) 5935123
Email friends_pharma@yahoo.com
SHORT DESCRIPTION OF
BUSINESS
Nature of Business Manufacture & Marketing of Pharmaceutical
Products
Year Established 1993
Registration # 0029342
Branches
Address 5/39, Lower Mall, Near Session
Courts, Lahore, Pakistan
Tel # 92
(42) 7240971 - 73 (3 Lines)
Fax # 92
(42) 7114410
Factory Location
31 K.M. Ferozepura Road,
Lahore, Pakistan
Auditors
Nazir Ahmad Chaudhri
(Chartered
Accountants)
Gardee Trust Building, Napier Road, Lahore,
Pakistan
Legal Status
Subject Company was established as a Private
Limited Company in 1993
Authorized Capital
Rs. 11,000,000/- divided into 1,100,000 shares of Rs. 10/- each
Issued & Paid up
Capital
Rs. 1,000,000/- divided into 100,000 shares of Rs. 10/- each
Details of Chief
Executive/ Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Nadeem Zafar Mr. Muhammad Iqbal Khan Mr. Abubakar Yousaf Mrs. Sajeela Sarwar |
Pakistani Pakistani Pakistani Pakistani |
14-C,
Aibak Block, New Garden Town, Lahore 14-C,
Aibak Block, New Garden Town, Lahore 14-C,
Aibak Block, New Garden Town, Lahore 14-C,
Aibak Block, New Garden Town, Lahore |
Business Business Business Business |
Chief Executive Director Director Director |
Shareholders
Names
Mr. Nadeem Zafar
Mr. Muhammad Iqbal Khan
Mr. Abubakar Yousaf
Mrs. Sajeela Sarwar
Associates
SUBSIDIARY
None
ASSOCIATED COMPANIES
Shannza (Private) Limited Pakistan
Products / Services
Manufacture & marketing of Pharmaceutical Products by its brand names
of ARTEMOSE, ARTISAF, BECLOTRIM, BEPRONATE, BETAMYCIN, BRAINAMAX, C DOXIME, CEDRATE,
CEFAROXIN, CEFROXIL, CIPFEN, COBAMIN, DERMICON, FAMCET, FLEXOREN, FLUFEND,
FLURASAID, FRELEXIN, FRENDCOGEN, FRENDIK P, FRENDIK S, FROXTIN, GYTRIM, GYTRIM
HC,INSTAZIN, INTEFRED, LEVOFEND, LIMICHOL, LORTAMINE, LOZAK, MEPRIUM, NIDACON,
PANGIT, PEPROZOL, PILOXIN, PLANODERM, PREZIT, PRISM, PROFER, SIMPID, TELUKAST,
ULCOZOL, VIOCEF, VIOXIME
Number of Employees
90
Annual Production
Volume
The capacity and production of the company’s
plant is indeterminable as it involves varying processes of manufacture.
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2006 |
100,000,000/- (Estimated) |
Authorized Distributors
Mainly in all major cities including Interior
Sindh & Interior Punjab Areas
Bankers
Habib Bank
Limited, Pakistan.(Mortgage obtained PKR 60,000,000/-)
The Bank of
Punjab, Pakistan.
Standard Chartered
Bank, Pakistan.
Memberships
·
Pakistan Pharmaceutical Manufacturers Association.(PPMA)
- Lahore Chamber of Commerce & Industry.(LCCI)
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 62.50 |
|
UK Pound |
1 |
Rs. 122.30 |
|
Euro |
1 |
Rs.
92.40 |
Comments
Subject Company was established in 1993 and
is engaged in manufacture & marketing of Pharmaceutical Products. Market reputation
is good. Trade relations are reported as fair. The Company can be considered
for normal business dealings at usual trade terms & conditions.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)